A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review
Loading...
Date
Authors
Saougou, I.
Papagoras, C.
Markatseli, T. E.
Voulgari, P. V.
Drosos, A. A.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Clin Rheumatol
Book name
Book series
Book edition
Alternative title / Subtitle
Description
This report seeks to describe the clinical efficacy and safety of infliximab in a patient with psoriatic arthritis on hemodialysis and to review the literature on the topic. We present a patient with psoriatic arthritis on hemodialysis treated with infliximab and we review the literature. Our case includes a patient with severe psoriasis and dactylitis with chronic renal failure requiring regular hemodialysis. At presentation the patient had a psoriasis area and severity index (PASI) score of 35.1 and dactylitis affecting the right thumb. Evaluation of laboratory parameters revealed a slight increase of erythrocyte sedimentation rate (21 mm/h) and a mild normocytic anemia (Hct 36.4). The rest of the laboratory and imaging tests were within normal limits. Infliximab was initiated at the loading dose of 5 mg/kg body weight at weeks 0, 2, 6, and every 8 weeks thereafter. On retreatment at week 14 the PASI score was measured to 3.4. After the conclusion of 6 months of treatment, the reduction of PASI score was sustained reaching the point of 0.8. In addition, dactylitis, as well as laboratory parameters, showed a striking improvement. On the other hand, during the same period of time, no changes of renal functions were noted and no complications were reported and the patient continued his hemodialysis on a regular basis. Our case is in accordance with other reports supporting that infliximab treatment in patients undergoing hemodialysis can be safe, well tolerated, and effective. However, larger trials are needed to prove its use in these patients.
Description
Keywords
Antibodies, Monoclonal/pharmacology/*therapeutic use, Arthritis, Psoriatic/complications/*drug therapy, Humans, Kidney Failure, Chronic/*complications/therapy, Male, Middle Aged, Renal Dialysis, Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/20490588
http://www.springerlink.com/content/k7477612m01501h4/fulltext.pdf
http://www.springerlink.com/content/k7477612m01501h4/fulltext.pdf
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής